DE60133014T2 - Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten - Google Patents

Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten Download PDF

Info

Publication number
DE60133014T2
DE60133014T2 DE60133014T DE60133014T DE60133014T2 DE 60133014 T2 DE60133014 T2 DE 60133014T2 DE 60133014 T DE60133014 T DE 60133014T DE 60133014 T DE60133014 T DE 60133014T DE 60133014 T2 DE60133014 T2 DE 60133014T2
Authority
DE
Germany
Prior art keywords
compound
compound according
alkyl
mmol
allergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60133014T
Other languages
German (de)
English (en)
Other versions
DE60133014D1 (de
Inventor
Neng-Yang North Caldwell SHIH
Daniel M. Edison SOLOMON
John J. Clinton Township PIWINSKI
Andrew T. Emerson LUPO
Michael J. Half Moon Bay GREEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60133014D1 publication Critical patent/DE60133014D1/de
Publication of DE60133014T2 publication Critical patent/DE60133014T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60133014T 2000-09-20 2001-09-18 Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten Expired - Lifetime DE60133014T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23405300P 2000-09-20 2000-09-20
US234053P 2000-09-20
PCT/US2001/029095 WO2002024659A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists

Publications (2)

Publication Number Publication Date
DE60133014D1 DE60133014D1 (de) 2008-04-10
DE60133014T2 true DE60133014T2 (de) 2009-02-26

Family

ID=22879692

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60133014T Expired - Lifetime DE60133014T2 (de) 2000-09-20 2001-09-18 Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten

Country Status (15)

Country Link
US (1) US6506756B2 (enExample)
EP (1) EP1318994B1 (enExample)
JP (1) JP2004509871A (enExample)
CN (1) CN1461303A (enExample)
AR (1) AR030946A1 (enExample)
AT (1) ATE387439T1 (enExample)
AU (1) AU2001292730A1 (enExample)
CA (1) CA2421826C (enExample)
DE (1) DE60133014T2 (enExample)
ES (1) ES2300364T3 (enExample)
HK (1) HK1052179A1 (enExample)
MX (1) MXPA03002448A (enExample)
MY (1) MY117975A (enExample)
TW (1) TW589303B (enExample)
WO (1) WO2002024659A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607862B2 (en) 2001-08-24 2003-08-19 Intel Corporation Damascene extreme ultraviolet lithography alternative phase shift photomask and method of making
RU2323935C2 (ru) * 2002-04-18 2008-05-10 Шеринг Корпорейшн Производные бензимидазола, их применение и фармацевтическая композиция на их основе, обладающая свойствами антагониста рецептора гистамина h3
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1-(4-哌啶基)苯并咪唑酮
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
NL1026634C2 (nl) * 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychofarmaceutisch preparaat en werkzame stof daarin.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9224955B1 (en) * 2014-10-31 2015-12-29 Feng-wen Yen Purifying method for organic optoelectronic material
CN113880808B (zh) * 2020-07-03 2024-12-31 合肥医工医药股份有限公司 一类三唑类化合物、制备方法及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
JPH0678315B2 (ja) * 1988-04-28 1994-10-05 シェリング・コーポレーション 新規なベンゾピリド‐ピペリジン、ピペリジリデンおよびピペラジン化合物、組成物、製造法および利用法
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
EP0448765B1 (de) 1990-03-30 1994-08-17 HEUMANN PHARMA GMBH & CO Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
AU662588B2 (en) 1991-12-18 1995-09-07 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine H3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1019050E (pt) 1997-06-24 2002-09-30 Novo Nordisk As Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
WO2000005215A1 (en) 1998-07-24 2000-02-03 Russinsky Limited A process for preparing benzocycloheptapyridin-11-ones

Also Published As

Publication number Publication date
CA2421826C (en) 2009-10-27
AU2001292730A1 (en) 2002-04-02
ES2300364T3 (es) 2008-06-16
US6506756B2 (en) 2003-01-14
EP1318994B1 (en) 2008-02-27
HK1052179A1 (zh) 2003-09-05
WO2002024659A3 (en) 2002-10-24
MXPA03002448A (es) 2003-06-19
ATE387439T1 (de) 2008-03-15
US20020086859A1 (en) 2002-07-04
MY117975A (en) 2004-08-30
DE60133014D1 (de) 2008-04-10
JP2004509871A (ja) 2004-04-02
WO2002024659A2 (en) 2002-03-28
CN1461303A (zh) 2003-12-10
CA2421826A1 (en) 2002-03-28
TW589303B (en) 2004-06-01
AR030946A1 (es) 2003-09-03
EP1318994A2 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
DE69628556T2 (de) Tricyclische verbindungen als inhibitoren von farnesyl protein transferase
DE60022386T2 (de) Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
DE60309598T2 (de) Als histamin-h3-antagonisten geeignete indolderivate
EP0877744B1 (de) Substituierte aza- und diazacycloheptan- und -cyclooctanverbindungen und deren verwendung
DE69919361T2 (de) Pyridyl-ether und -thioether als nikotin-acetylcholin-rezeptorliganden und ihre therapeutische anwendung
EP1228060A1 (de) Arylalkane, arylalkene und aryl-azaalkane, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69819903T2 (de) Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
KR20140124398A (ko) 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘
DE69922528T2 (de) N-imidazolyl-alkyl substituierte cyklische amine als histamin-h3 agonisten oder antagonisten
DE602004009796T2 (de) Imidazolderivate als glutamatrezeptorantagonisten
DE69414855T2 (de) N-(piperidinyl-1-alkyl)-substituierte cyclohexancarbonsäureamide als 5ht1a rezeptor antagonisten
DE60107586T2 (de) Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
DE69825608T2 (de) Benzo[5,6]cycloheptapyridin derivate anwendbar als farnesyl protein transferase inhibitoren
EP1318994B1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
DE69920516T2 (de) Substituierte oxime und hydrazone als neurokinin antagonisten
DE69634183T2 (de) Substituierte Heterocyclen
DE69926078T2 (de) Farnesyl-protein transferase inhibitoren
DE69827614T2 (de) Chinoxalindionen
EP1318993B1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
EP1318983B1 (en) Substituted imidazoles as histamine h1 and h3 agonists or antagonists
DE69722002T2 (de) Tricyclische n-cyanoimine als inhibitoren der farnesyl-protein transferase
DE69817826T2 (de) Benzo[5,6]cyclohepta[1,2b]pyridine derivate anwendbar als farnesyl protein transferase inhibitoren
DE69724130T2 (de) Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl protein transferase inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition